Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the compensation committee of the company's board of directors granted six new employees options to purchase a total of 64,050 shares of the company's common stock at an exercise price per share of $30.30, which was the closing price on february 8, 2022, and restricted stock units to acquire a total of 2,025 s
RCUS Ratings Summary
RCUS Quant Ranking